VYVGART demonstrated clinically meaningful benefit across all AChR-Ab seronegative gMG subtypes in ADAPT SERON, supporting broad role of pathogenic IgGs in disease activityFinal ADAPT SC+ results show ...
Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that ...
Visual content depicting climate activists emphasizes emotion and disruption, contrasting with the rational, data-driven ...
Business.com on MSN
Dizzying Data: What the Rise in Data Complexity Means for Business
Companies use customer data in their decision-making, but they must know how to wield it properly. Here is the best way to ...
In the treatment of cardiometabolic disease, much has changed in the past 20 years, especially with the emergence of novel ...
Compelling results set new clinical standard in generalized myasthenia gravis (gMG), increasing confidence in the Company's registrational KYSA-6 Phase 3 MG trial 100% of patients achieved clinically ...
The everolimus scaffold, which had mostly disappeared by 3 years, was still associated with fewer reinterventions than PTA.
A groundbreaking study reveals promising efficacy and safety of 212Pb-DOTAMTATE for treating neuroendocrine tumors, paving the way for future trials.
Research and Development Expenses -- $9.6 million in the third quarter of 2025, down from $12.3 million in Q3 2024, due to ...
Shares fall as traders abandon rate bets after core CPI tops forecasts; Nick Scali sees strong sales; Woolworths sales miss; ...
YL VANCOUVER, BC, Oct. 27, 2025 /CNW/ – Walker Lane Resources Ltd. (TSXV: WLR) (Frankfurt: 6YL); “Walker Lane”) is pleased to ...
Australian shares are poised to advance; Apple reaches $US4trn mark; Microsoft secures OpenAI stake; results pending from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback